Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). - Wikidata - awgldk - TriplyDB

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

http://www.wikidata.org/entity/Q52569827

about

Acute Myeloid Leukemia: A Concise Review Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis Molecular Genetic Markers in Acute Myeloid Leukemia Extramedullary Manifestations of Myeloid Neoplasms TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.CBFbeta is critical for AML1-ETO and TEL-AML1 activity.Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling.High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Comprehensive mutational profiling of core binding factor acute myeloid leukemia.The genomic landscape of core-binding factor acute myeloid leukemias Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.Overexpression and knockout of miR-126 both promote leukemogenesis FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

P2860

Q26766719-AEE65E53-F171-405E-B384-021A78BBBCBA Q26771740-B8A5F9D6-DFF3-4237-BA57-7708E61CC67D Q26799606-32158B70-E11B-40D3-B7E7-6304606C77C4 Q26799783-24D8F1ED-5358-4E3D-B883-FA1FB717E371 Q27853009-001DB19D-4633-4887-81D3-31FDB65661A9 Q28075654-676960C8-A481-42CF-A6DC-31CB495C3CE3 Q30252938-72C8AF78-78D3-453E-9789-3F660430C945 Q30439864-CB85E7AC-52FB-4F02-9EC5-D1FBB9C7AF08 Q33421005-17B8D478-3780-439C-B9A6-9ED40FC6FF47 Q33558141-00FAAD38-D04A-4484-A4C3-2A9CD76DF47B Q33574172-52ABE5A9-C242-4CA4-8513-DE74BDEF1028 Q33667247-8400B0F4-F336-482B-9C86-63652908E052 Q33737479-A8A842FD-7909-434F-86AB-825C99539406 Q33754603-A8E68D0E-9F09-4534-B750-CF3C1795D1E1 Q33758306-E17351DB-9A34-4D93-9F73-68C1C26E0D09 Q33901968-45BEDB20-67B1-4E33-BD3D-77FF1A35CF2D Q34106837-46560FB3-D312-40DA-9A7B-8E9841FC6F0F Q34169601-5CCFC4C6-7BB3-4E14-A828-2FA438EF05E6 Q34285937-80CED72B-2D64-446F-9739-2116A89F94DD Q34428556-22D65136-F602-487C-B3D8-77DAD22A6BCC Q34572894-22E5825C-D63E-4C23-96D4-6CCBCDC9D7C4 Q34598109-D58F87AF-FF4C-4C91-8C46-D37AA0866519 Q34647741-8922FFE0-1D13-4772-9BC7-EFE2AC8D77AD Q34663691-50553547-B579-4430-A4AB-BA02FB9EBCEF Q34664111-8FD3C0A6-FCFA-43FA-98CD-85CBB1D4223B Q34684285-ECCA6785-68BC-447A-9517-2E4BB91945BB Q34792228-FB89679E-317D-4146-B3A8-D572B198232E Q35332017-0A49CD7F-82ED-4F81-8685-4F2C4325FBC5 Q35361598-21A0A6E0-F9E6-49EE-B0A7-0BE8D1B6E003 Q35669870-DB5E552C-DA68-4727-B798-1C50FB9253DF Q35776437-C958F608-A363-4663-A048-D8CDA729E8C1 Q35776442-37813523-C677-455D-8032-22511AA8FF07 Q36065836-739E4CD7-3B68-41E0-8F58-0A23A9364FDC Q36141933-8B379F19-C6A6-4A27-9E50-C907923E290D Q36193187-A02653F3-5E1A-4D84-88CC-CDCADF8C52C0 Q36407239-F7776A91-6695-412E-9D85-977A4F920FA8 Q36548080-5ACBD414-AB77-40DD-8445-9D20CFA53778 Q36750458-52EA2C21-DC47-4B55-B3E9-3BCE0AEFF7C9 Q36784704-CFFFF00F-D9B1-45E6-ACDB-498D6C0DC7B0 Q36919799-08987696-0E06-4E47-9E03-764B6568527C

P2860

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).

http://www.wikidata.org/entity/Q52569827

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@en

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@nl

type

label

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@en

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@nl

prefLabel

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@en

Incidence and prognostic impac ...... te myeloid leukemia (CBF-AML).

@nl

P1433

Q52569827-45220C69-4FAD-4A55-810A-D9FBE5C00155

P1476

Q52569827-636D02C4-193D-42C4-B51A-3BB321025D3F

P2093

Q52569827-2591AD60-814B-4579-8E6F-985E858F17B1

Q52569827-4462519C-26F8-422F-8FFF-DB85CB565A39

Q52569827-4D944D52-AB47-433A-A717-2C993FEDF545

Q52569827-6CE24397-C834-405A-AF24-AD4E99C53D94

Q52569827-84D5AF0F-3FDC-4AE6-B45A-23DD9B1F9AB4

Q52569827-85EF2ADB-B979-4797-8AA0-01C02C996708

Q52569827-9F49B605-0FE2-4D32-A595-E5BFB4387DC0

Q52569827-BD1E7C3D-4729-4BAE-ACF1-B5D3FB36B0AF

Q52569827-CEE43D39-92D0-4E5B-BB5C-2B5CCB61CBA4

Q52569827-CFBD4F7A-CF25-4739-98ED-95603A88E548

P2888

Q52569827-2F59303C-BFF0-4448-8739-E5957F0E97E7

P304

Q52569827-71B893FD-F751-45F5-804C-E8272D79C39E

P31

Q52569827-C05E3937-AAF3-40D5-B05A-ADA5DD976D26

P356

Q52569827-2F4C0D41-ACA0-448C-8642-BC9F2AB5EEBC

P433

Q52569827-88C55C9D-09C8-4326-B149-49F85B5E77E1

P478

Q52569827-3C2777D2-101A-43CF-AC90-D0305488D197

P50

Q52569827-2FE8EAB3-30B0-4AD9-AEB3-EED185EF8C64

Q52569827-616696B3-43E4-4C15-B5DC-739FE3162BD0

Q52569827-7E95FFD7-E6A1-4064-8F41-54A1AA40C17C

P577

Q52569827-EF937BF6-FB72-4467-82E0-6A8602D44EFA

P5875

Q52569827-848C5B04-BE6F-41DF-AC60-8E72129BCBB1

P698

Q52569827-F4D663D5-DB3B-46D7-A5DD-E29404C9D904

P921

Q52569827-E9D091B1-97F1-4C7D-844F-FE18015DD8B4

P356

P1433

P1476

Incidence and prognostic impac ...... ute myeloid leukemia (CBF-AML)

@en

P2093

A Auvrignon

http://www.w3.org/2001/XMLSchema#string

A Baruchel

http://www.w3.org/2001/XMLSchema#string

Acute Leukemia French Association (ALFA)

http://www.w3.org/2001/XMLSchema#string

B Brethon

http://www.w3.org/2001/XMLSchema#string

E Raffoux

http://www.w3.org/2001/XMLSchema#string

G Leverger

http://www.w3.org/2001/XMLSchema#string

H Dombret

http://www.w3.org/2001/XMLSchema#string

H Leroy

http://www.w3.org/2001/XMLSchema#string

Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups

http://www.w3.org/2001/XMLSchema#string

N Boissel

http://www.w3.org/2001/XMLSchema#string

P2888

P304

965-970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2404188

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Claude Preudhomme

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7182077

http://www.w3.org/2001/XMLSchema#string

P698

16598313

http://www.w3.org/2001/XMLSchema#string

P921